NASDAQ:NKNantkwest Stock Price, Forecast & News

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NK shares have increased by 219.9% and is now trading at $11.26. View which stocks have been most impacted by Coronavirus.

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Nantkwest.

Nantkwest Inc (NASDAQ:NK) announced its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. Nantkwest had a negative return on equity of 51.94% and a negative net margin of 112,350.85%. View Nantkwest's earnings history.

News articles about NK stock have been trending very negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nantkwest earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Nantkwest.

Nantkwest saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 4,310,000 shares, a decrease of 11.9% from the May 31st total of 4,890,000 shares. Based on an average daily trading volume, of 1,340,000 shares, the short-interest ratio is currently 3.2 days. Currently, 15.4% of the shares of the company are short sold. View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Alector (ALEC), Bill.com (RVMD), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT) and Adverum Biotechnologies (ADVM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Mallinckrodt (MNK), Opko Health (OPK), Amicus Therapeutics (FOLD), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Bausch Health Companies (BHC) and Fate Therapeutics (FATE).

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NK stock can currently be purchased for approximately $11.26.

Nantkwest has a market capitalization of $1.11 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

The official website for Nantkwest is www.nantkwest.com.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]